Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Fatma Bulushi, Rahma Al-Riyami, MD, Zainab Al Hosni, MD, Bushra Al-Abri, Murtadha Al-Khabori, MD

Blood (2019) 134 (Supplement_1): 2604.

https://doi.org/10.1182/blood-2019-128402

Published: 2019

Journal Articles

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Satoko Morishima, MD PhD, Kenji Ishitsuka, MD PhD, Koji Izutsu, MD PhD, Shigeru Kusumoto, MD PhD, Junya Makiyama, MD PhD, Atae Utsunomiya, MD, Kisato Nosaka, MD PhD, Takashi Ishida, MD PhD, Yoshitaka Imaizumi, MD PhD, Nobuhiko Yamauchi, MD, Kazushi Araki, DVM, PhD, Nobuaki Adachi, PhD, Tomonari Yamashita, Ryo Atsumi, PhD, Kunihiro Tsukasaki, MD PhD, Kensei Tobinai, MD PhD

Blood (2019) 134 (Supplement_1): 4025.

https://doi.org/10.1182/blood-2019-125507

Published: 2019

Journal Articles

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

Julia Stomper, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Annette Schmitt-Graeff, Michael Lübbert

Blood (2019) 134 (Supplement_1): 1422.

https://doi.org/10.1182/blood-2019-128231

Published: 2019

Journal Articles

RNA Editing of Tumor Suppressor Mir-26a Promotes Malignant Progenitor Propagation in Chronic Myeloid Leukemia

Raymond H Diep, Qingfei Jiang, PhD, Jane Isquith, MS, Maria A. Zipeto, PhD, Jessica Pham, Nathan Delos Santos, BS, Julisia Chau, B.S., Sheldon Morris, MD MPH, Catriona Jamieson, MD PhD

Blood (2018) 132 (Supplement 1): 2611.

https://doi.org/10.1182/blood-2018-99-116988

Published: 2018

Journal Articles

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

Faisal Basheer, MBBChir, MA, George Giotopoulos, PhD, Eshwar Meduri, PhD, Haiyang Yun, PhD, Milena Mazan, PhD, Olivia Sheppard, Daniel Sasca, MD, Malgorzata Gozdecka, PhD, George S. Vassiliou, MD PhD, Brian J.P Huntly

Blood (2017) 130 (Supplement 1): 1215.

https://doi.org/10.1182/blood.V130.Suppl_1.1215.1215

Published: 2017

Journal Articles

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Daisuke Honma, PhD, Nobuaki Adachi, PhD, Osamu Kanno, PhD, Jun Watanabe, Makoto Hirasawa, Emi Nosaka, Machiko Shiroishi, Takeshi Takizawa, Isao Yasumatsu, Takao Horiuchi, PhD, Akira Nakao, PhD, Keisuke Suzuki, Tomonori Yamasaki, Katsuyoshi Nakajima, Miho Hayakawa, Takanori Yamazaki, Kazushi Araki, D.V.M., PhD, Kosaku Fujiwara, PhD

Blood (2017) 130 (Supplement 1): 2073.

https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073

Published: 2017

Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Blood (2017) 130 (Supplement 1): 2745.

https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745

Published: 2017

Journal Articles

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Timothy A. Yap, MD PhD, Jane N. Winter, MD, John P. Leonard, MD, Vincent Ribrag, MD, Anastasia Constantinidou, MD, Lisa Giulino-Roth, MD, Jean-Marie Michot, MD, Tariq A Khan, MD, Thierry Horner, PhD, Jennifer Carver, Teodora Pene Dumetrescu, PhD, Zangdong He, PhD, Michael T. McCabe, PhD, Caretha L. Creasy, PhD, Arindam Dhar, MBBS, MD PhD, Christopher Carpenter, MD PhD, Peter M Johnson, MA, MD

Blood (2016) 128 (22): 4203.

https://doi.org/10.1182/blood.V128.22.4203.4203

Published: 2016

Journal Articles

Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Briana Gibson, MD, Rahul Matnani, MBBS, PhD, Zheng Ping, MD, Balabhadrapatruni VSK Chakravarthi, Yang Yang, MD PhD, Sooryanarayana Varambally, PhD, Denise Peker, MD

Blood (2016) 128 (22): 4216.

https://doi.org/10.1182/blood.V128.22.4216.4216

Published: 2016

Journal Articles

Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Low and High Grade B-Cell Non-Hodgkin Lymphomas and Differential Regulation of EZH2 Expression By p-ERK and MYC in High Grade B Cell Lymphomas

Xuejun Tian, MD/PhD, Ali Shahsafaei, David M. Dorfman, MD PhD

Blood (2015) 126 (23): 2660.

https://doi.org/10.1182/blood.V126.23.2660.2660

Published: 2015

Journal Articles

A Patient-Derived EZH2 Mutant Induces MDS-like Diseases with Derepressed ABCG2 Expression in Mice

Kimihito Cojin Kawabata, MD PhD, Daichi Inoue, MD PhD, Jiro Kitaura, MD PhD, Yuka Harada, MD PhD, Susumu Goyama, MD PhD, Hironori Harada, MD PhD, Hiroyuki Aburatani, MD PhD, Toshio Kitamura, MD PhD

Blood (2015) 126 (23): 4116.

https://doi.org/10.1182/blood.V126.23.4116.4116

Published: 2015

Journal Articles

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Taylor S Harding, B.A., Jessica Swanson, Brian Van Ness, PhD

Blood (2014) 124 (21): 5719.

https://doi.org/10.1182/blood.V124.21.5719.5719

Published: 2014

Journal Articles

Ezh2 Is An Essential Regulator Of T-Cell Development and Oncogenic Transformation

Camille Simon, Jalila Chagraoui, PhD, Jana Krosl, PhD, Josee Hebert, MD, Guy Sauvageau, MD, PhD

Blood (2013) 122 (21): 3729.

https://doi.org/10.1182/blood.V122.21.3729.3729

Published: 2013

Journal Articles

Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas

Kejie Zhang, MD, PhD, Lan V Pham, PhD, Archito T. Tamayo, MS, John Lee, MD, Jerry Bryant, M.S., Anas Younes, MD, Luis E Fayad, MD, David J Yang, Ph.D, Richard J. Ford, MD, PhD

Blood (2012) 120 (21): 1305.

https://doi.org/10.1182/blood.V120.21.1305.1305

Published: 2012

Journal Articles

MicroRNA-101 Is Down-Regulated In PV and ET Granulocytes and Its Decrease Is Associated with Over-Expression of Histone Methyltransferase In EZH2 In MPN Patients

Sabina Swierczek, PhD, Donghoon Yoon, PhD, Kimberly Hickman, BS, Josef T. Prchal, MD

Blood (2010) 116 (21): 1989.

https://doi.org/10.1182/blood.V116.21.1989.1989

Published: 2010

Journal Articles

Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets

Blood (2010) 116 (21): 632.

https://doi.org/10.1182/blood.V116.21.632.632

Published: 2010

Journal Articles

Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis

Vibe Skov, PhD, Thomas Stauffer Larsen, MD, PhD, Mads Thomassen, PhD, Caroline Riley, MD, Morten Krogh Jensen, MD, DMSc, Ole Weis Bjerrum, MD, DMSc, Torben A Kruse, Hans Carl Hasselbalch, MD, DMSc

Blood (2010) 116 (21): 4118.

https://doi.org/10.1182/blood.V116.21.4118.4118

Published: 2010

Journal Articles

Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin.

Blood (2009) 114 (22): 139.

https://doi.org/10.1182/blood.V114.22.139.139

Published: 2009

Journal Articles

Possible Epigenetic Regulation of Functionally Opposing Groups of Genes Involved in Ex Vivo Expansion of Cord Blood Stem Cells

Sudhakar Baluchamy, PhD, Benjamin Petro, BS, Hiroto Araki, MD, PhD, Valerie Lindgren, PhD, Nadim Mahmud, MD, PhD

Blood (2008) 112 (11): 3473.

https://doi.org/10.1182/blood.V112.11.3473.3473

Published: 2008

Journal Articles

Bypassing Cellular Senescence by Ezh2 .

Leonie M. Kamminga, MSc, Leonid Bystrykh, PhD, Sita Houwer, Jose Douma, Ellen Weersing, Bert Dontje, Gerald de Haan, PhD

Blood (2004) 104 (11): 2776.

https://doi.org/10.1182/blood.V104.11.2776.2776

Published: 2004

NARROW

Impact of Mutations in Epigenetic Modifiers in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL)

Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients

RNA Editing of Tumor Suppressor Mir-26a Promotes Malignant Progenitor Propagation in Chronic Myeloid Leukemia

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM)

Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Differential Expression of Enhancer of Zeste Homolog 2 (EZH2) Protein in Low and High Grade B-Cell Non-Hodgkin Lymphomas and Differential Regulation of EZH2 Expression By p-ERK and MYC in High Grade B Cell Lymphomas

A Patient-Derived EZH2 Mutant Induces MDS-like Diseases with Derepressed ABCG2 Expression in Mice

Modeling Myeloma Treatment through Epigenetic Modification: Synergistic Combination of EZH2 and Histone Deacetylase Inhibitors

Ezh2 Is An Essential Regulator Of T-Cell Development and Oncogenic Transformation

Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas

MicroRNA-101 Is Down-Regulated In PV and ET Granulocytes and Its Decrease Is Associated with Over-Expression of Histone Methyltransferase In EZH2 In MPN Patients

Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets

Enhanced Gene Expression of EZH2 In Patients with Primary Myelofibrosis

Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin.

Possible Epigenetic Regulation of Functionally Opposing Groups of Genes Involved in Ex Vivo Expansion of Cord Blood Stem Cells

Bypassing Cellular Senescence by Ezh2 .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only